GlobeNewswire: Intellia Therapeutics, Inc. Contains the last 10 of 201 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:19:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2847698/0/en/Intellia-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-3-MAGNITUDE-Study-of-NTLA-2001-as-a-Single-Dose-CRISPR-Based-Treatment-for-Transthyretin-Amyloidosis-with-Cardiomyo.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy2024-03-18T11:30:00Z<![CDATA[CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of transthyretin (ATTR) amyloidosis. The MAGNITUDE trial is evaluating the efficacy and safety of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy.]]>https://www.globenewswire.com/news-release/2024/02/22/2833580/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress2024-02-22T12:30:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/15/2829852/0/en/Intellia-Therapeutics-and-ReCode-Therapeutics-Announce-Strategic-Collaboration-to-Develop-Novel-Gene-Editing-Therapies-for-Cystic-Fibrosis.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis2024-02-15T12:30:00Z<![CDATA[CAMBRIDGE, Mass. and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF). CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestive systems and other organs. CF can result in life-threatening infections, respiratory failure and other serious complications.]]>https://www.globenewswire.com/news-release/2024/02/14/2828990/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Earnings-and-Company-Updates.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates2024-02-14T12:30:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m. ET.]]>https://www.globenewswire.com/news-release/2024/01/31/2821597/0/en/Intellia-Therapeutics-Announces-Publication-of-Positive-Interim-Phase-1-Data-for-NTLA-2002-in-Patients-with-Hereditary-Angioedema-in-the-New-England-Journal-of-Medicine.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine2024-01-31T22:00:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim results from the Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine (NEJM). NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.]]>https://www.globenewswire.com/news-release/2024/01/04/2804303/0/en/Intellia-Therapeutics-Highlights-its-Three-Year-Strategic-Priorities-and-Anticipated-2024-Key-Milestones.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones2024-01-04T21:01:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced its strategic priorities through 2026 and key anticipated 2024 milestones that support the company’s mission to transform the lives of patients and bring forth a new era in medicine.]]>https://www.globenewswire.com/news-release/2023/11/14/2779956/0/en/Intellia-Therapeutics-Receives-European-Union-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-In-Vivo-CRISPR-Genome-Editing-Treatment-for-Hereditary-Angioedema.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema2023-11-14T12:30:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.]]>https://www.globenewswire.com/news-release/2023/11/09/2777239/0/en/Intellia-Therapeutics-Announces-Third-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress2023-11-09T12:30:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2023.]]>https://www.globenewswire.com/news-release/2023/11/02/2772118/0/en/Intellia-Presents-New-Interim-Data-from-the-Ongoing-Phase-1-Study-of-NTLA-2001-at-the-4th-International-ATTR-Amyloidosis-Meeting.html?f=22&fvtc=4&fvtv=28713Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting2023-11-02T11:00:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today presented additional interim results from its ongoing Phase 1 study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. Results were presented in an oral presentation at the 4th International ATTR Amyloidosis Meeting, held Nov. 2–3 in Madrid, Spain.]]>https://www.globenewswire.com/news-release/2023/10/26/2767384/0/en/Intellia-Therapeutics-to-Present-Updated-Data-from-Ongoing-Phase-1-Study-of-NTLA-2001-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis-and-Hold-Conference-Call-to-Discuss-Third-.html?f=22&fvtc=4&fvtv=28713Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November2023-10-26T11:30:00Z<![CDATA[CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upcoming events in November.]]>